Is Adeshwar Meditex overvalued or undervalued?

As of 7 November 2025, Adeshwar Meditex has moved from an expensive to a fair valuation grade. The company is currently fairly valued, with a PE ratio of 12.77, an EV to EBITDA of 8.25, and an EV to Sales ratio of 0.43. In comparison to its peers, Poly Medicure is very expensive with a PE ratio of 53.67, while BPL stands out as very attractive with a PE ratio of 6.38.
Despite the recent fair valuation, Adeshwar Meditex has underperformed relative to the Sensex, particularly over the year with a stock return of -18.38% compared to the Sensex's 4.62%. This discrepancy highlights the potential for future growth as the company aligns its performance with market expectations.